• Please log in or register to access this feature.

Original Article

You have full text access to this OnlineOpen article

Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy

  1. Herbert L. Bonkovsky M.D.1,2,*,
  2. J. Michael Woolley3

Article first published online: 30 DEC 2003

DOI: 10.1002/hep.510290124

Issue

Hepatology

Hepatology

Volume 29, Issue 1, pages 264–270, January 1999

Additional Information

How to Cite

Bonkovsky, H. L. and Woolley, J. M. (1999), Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology, 29: 264–270. doi: 10.1002/hep.510290124

Author Information

  1. 1

    Departments of Medicine, Biochemistry and Molecular Biology and Thousand Oaks, CA

  2. 2

    The Liver-Biliary-Pancreatic Center, UMass/Memorial Health Care and The University of Massachusetts Medical School, Worcester, MA; and Thousand Oaks, CA

  3. 3

    Department of Health Economics, Amgen Inc, Thousand Oaks, CA

*University of Massachusetts Medical Center, 55 Lake Avenue, North, Room S6-737, Worcester, MA 01655 fax: (508) 856-3981

Publication History

  1. Issue published online: 30 DEC 2003
  2. Article first published online: 30 DEC 2003
  3. Manuscript Accepted: 26 OCT 1998
  4. Manuscript Received: 11 JUN 1998

Funded by

  • Amgen Inc., Thousand Oaks, CA
  • Dr. Bonkovsky also came from the United States Public Health Service. Grant Number: NIH Grant DK 38825
  • United States Public Health Service

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (163K)

References

  • 1
    Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26(Suppl):62S–65S.MEDLINE
    Direct Link:
  • 2
    Seeff LB. Natural history of hepatitis C. Hepatology 1997; 26(Suppl):21S–28S.MEDLINE
    Direct Link:
  • 3
    Alter HJ, Loury-Cantilena C, Melpolder J, Tan D, Van Raden M, Henrion D, Lau D, et al. Hepatitis C in asymptomatic blood donors. Hepatology 1997; 26(Suppl):29S–33S.MEDLINE
    Direct Link:
  • 4
    Ware JE, Bungay K, Gandek B, Bayliss M. Assessment of the health-related quality of life (HQL) of patients with chronic hepatitis C (CHC). Gastroenterology 1994; 106:A393.
  • 5
    Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, et al. Assessing health-related quality of life in chronic hepatitis C using the sickness impact profile. Clin Ther 1994; 16:334–343.MEDLINE
  • 6
    Carithers RL, Sugano D, Bayliss M. Health assessment for chronic HCV infection. Dig Dis Sci 1996; 41(Suppl):75S–80S.MEDLINE
  • 7
    Bayliss M, Gandek B, Bungay KM, Sugano D, Hsu MA, Ware JE. A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Qual Life Res 1998; 7:39–55.MEDLINE
  • 8
    Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27:209–212.MEDLINE
    Direct Link:
  • 9
    Hunt C, Dominitz J, Bute BP, Waters B, Blasi U, Williams D. Effect of interferon treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci 1997; 42:2482–2486.MEDLINE
  • 10
    Tong MJ, Reddy KR, Lee WM, Pockros PJ, Hoefs JC, Keefe EB, Hollinger FB, et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Hepatology 1997; 26:747–754.MEDLINE
    Direct Link:
  • 11
    Davis GA, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. N Engl J Med 1989; 321:1501–1506.MEDLINE
  • 12
    Reichard O, Foberg U, Fryden A, Mattsson L, Norkrans G, Sonnerborg A, Wejstal R, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-α2b for 60 weeks. Hepatology 1994; 19:280–285.MEDLINE
    Direct Link:
  • 13
    Poynard T, Leroy V, Cohard M, Thvenot T, Mathurin P, Opolon P, Zarski JP. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24:778–789.MEDLINE
    Direct Link:
  • 14
    Carithers RL, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 1997; 26(Suppl):83S–88S.MEDLINE
    Direct Link:
  • 15
    Romeo R, Pol S, Berthelot P, Brechot C. Eradication of hepatitis C virus RNA after alpha-interferon therapy. Ann Intern Med 1994; 121:276–277.MEDLINE
  • 16
    Reichard O, Glaumann H, Fryden A, Norkrans G, Schvarcz R, Sonnerborg A, Yun Z-B, et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology 1995; 21:918–922.MEDLINE
  • 17
    Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy. Ann Intern Med 1997; 127:875–881.MEDLINE
  • 18
    Thalji L, Haggerty CC, Rubin R, Berckmans TR, Pardee BL. 1990 National Survey of Functional Health Status: Final Report. Chicago, IL: National Opinion Research Center, 1992.
  • 19
    Stewart AL. Ware Jr JE. Measuring Functioning and Well-Being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press, 1992.
  • 20
    Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Medical Care 1992; 30:473–483.MEDLINE
  • 21
    McHorney CA, Ware JE, Lu JFR, Sherbourne CD. The MOS 36-Item Short-form Health Survey (SF-36): III. Tests of data quality, scaling assumptions and reliability across diverse patient groups. Medical Care 1994; 32:40–66.MEDLINE
  • 22
    McHorney CA, Ware JE, Raczek AE. The MOS 36-item short-form health status survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Medical Care 1993; 31:247–263.MEDLINE
  • 23
    Brazier JE, Harper R, Jones NMB, O'Cathain A, Thomas KJ, Usherwood T, Westlake L. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992; 305:160–164.MEDLINE
  • 24
    Katz JN, Larson MG, Phillips CB, Fossel AH, Liang MH. Comparative measurement sensitivity of short and longer health status instruments. Med Care 1992; 30:917–925.MEDLINE
  • 25
    Garratt AM, Ruta DA, Abdalla MI, Buckingham JK, Russell IT. The SF-36 health survey questionnaire: an outcome measure suitable for routine use within the NHS? BMJ 1993; 306:1440–1444.MEDLINE
  • 26
    Phillips RC, Lansky DJ. Outcomes management in heart valve replacement surgery: early experience. J Heart Valve Dis 1992; 1:42.MEDLINE
  • 27
    Kurtin PS, Davies AR, Meyer KB, DeGiacomo JM, Kantz ME. Patient-based health status measures in outpatient dialysis: early experiences in developing an outcomes assessment program. Med Care 1992; 30:MS136–MS149.
  • 28
    Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: New England Medical Center, The Health Institute, 1993.
  • 29
    Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127:855–865.MEDLINE
  • 30
    Kim WR, Poterucha JJ, Hermans JE, Therneau TM, Dickson ER, Evans RW, Gross JB, et al. Cost-effectiveness of 6 and 12 months of interferon therapy for chronic hepatitis C. Ann Intern Med 1997; 127:866–874.MEDLINE
  • 31
    McHutchison JG, Woolley JM, Nyberg LM. Cost effectiveness of consensus interferon therapy for chronic HCV infection [Abstract]. Hepatology 1997; 26(Suppl):421A.
  • 32
    McHutchison JG, Woolley JM, Nyberg LM. Cost effectiveness of retreatment with consensus interferon for chronic hepatitis C [Abstract]. Hepatology 1997; 26(Suppl):421A.
Get PDF (163K)